BPG is committed to discovery and dissemination of knowledge
Articles in Press
7/30/2020 5:38:02 AM | Browse: 61 | Download: 12
Publication Name World Journal of Gastroenterology
Manuscript ID 54515
Country/Territory Australia
Category Gastroenterology and Hepatology
Manuscript Type Retrospective Cohort Study
Article Title Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford
Manuscript Source Unsolicited Manuscript
All Author List Samba Siva Reddy Pulusu, Ashish Srinivasan, Krupa KrishnaPrasad, Daniel Cheng, Jakob Begun, Charlotte Keung, Daniel Van Langenberg, Lena Thin, Tamara Mogilevski, Peter De Cruz, Graham Radford-Smith, Emma Flanagan, Sally Bell, Soleiman Kashkooli, Miles Sparrow, Simon Ghaly, Peter Bampton, Elise Sawyer, Susan Connor, Quart-Ul-Ain Rizvi, Jane M Andrews, Gillian Mahy, Paola Chivers, Simon Travis and Ian Craig Lawrance
Funding Agency and Grant Number
Corresponding author Ian Craig Lawrance, FRCP (Hon), MBBS, PhD, Professor, Centre for Inflammatory Bowel Diseases, St John of God Hospital, 25 McCourt Street, Subiaco 6008, Western Australia, Australia. ian.lawrance@uwa.edu.au
Keywords Vedolizumab; Ulcerative colitis; Outcomes
Core Tip Vedolizumab (VDZ) is a gut selective anti-integrin used for treatment of Ulcerative colitis (UC). Evidence is needed to support its use in real life setting involving multiple centers and two countries to reduce physician, site and country biases. This is a retrospective review of prospectively collected database involving 303 UC patients from Australia and Oxford, United Kingdom treated with VDZ. Clinical response was observed in 79% of patients at 3 mo and clinical remission in 56%, 62% and 60% at 3 mo, 6 mo and 12 mo respectively. Anti-tumor necrosis factor (anti-TNF) naïve patients were 1.8 times more likely to achieve remission than anti-TNF exposed and 11% of patients required colectomy by 12 mo. We concluded that VDZ is a safe and effective biologic medication used for treatment of UC.
Citation Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi Q, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; In press
2020-04-04 11:32
Peer-Review Started
2020-04-04 11:33
To Make the First Decision
Return for Revision
2020-04-26 21:10
2020-07-18 04:47
Second Decision
2020-07-28 10:19
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-07-30 05:38
Articles in Press
2020-07-30 05:38
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Ya-Juan Ma
Reviewer Code 03261497
Editorial Director
Journal Chief Editor
Company Chief Editor Lian-Sheng Ma
Language Editor
Electronic Editor
Responsible Electronic Editor
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma
Manuscript File 54515-Review.docx
Answering Reviewers 54515-Answering reviewer(s).pdf
Audio Core Tip 54515-Audio core tip.m4a
Biostatistics Review Certificate 54515-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form 54515-Conflict-of-interest statement.pdf
Copyright License Agreement 54515-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 54515-Informed consent statement.pdf
Institutional Review Board Approval Form or Document 54515-Institutional review board statement.pdf
Peer-review Report 54515-Peer-review(s).pdf
Scientific Misconduct Check 54515-Scientific misconduct check.pdf
Scientific Editor Work List 54515-Scientific editor work list.pdf